ABSTRACT
OBJECTIVE：To investigate the effects of rabepr azole on the pharmacokinetic characteristics of clopidogrel and its active metabolite in healthy volunteers with different CYP2C19 genotypes. METHODS ：Healthy volunteers were selected as subjects，and then randomly divided into extensive metabolizer （EM）group，intermediate metabolizer （IM）group，and poor metabolizer（PM）group with 8 subjects in each group ，according to their CYP2C19 genotypes by random number table. In single-dose，randomized，open，two-cycle-crossover design ，each group was given Clopidogrel bisulfate tablets 300 mg or Clopidogrel bisulfate tablets 300 mg+Rabeprazole sodium enteric-coated tablets 20 mg. UPLC-MS/MS method was adopted to detect the concentration of clopidogrel and its active metabolite derivative （MP-H4）. The pharmacokinetic parameters were calculated and compared by DAS 2.0 software. RESULTS ：There was no statistical significance in clinical data as age ，height， body weight ，liver enzymes and serum creatinine among 3 kinds of metabolism subjects （P＞0.05）. Compared with subjects receiving clopidogrel alone ，cmax and AUC 0－t of clopidogrel of subjects combined with rabeprazole in EM group were increased by 36％ and 27％，while those of MP-H 4 were decreased by 34％ and 28％（P＜0.01）；cmax and AUC 0－t of clopidogrel of subjects combined with rabeprazole in IM group were increased by 19％ and 18％，while those of MP-H 4 were decreased by 19％ and 16％ （P＜0.05 or P＜0.01）；there was no statistical significance in cmax and AUC 0－t of clopidogrel and MP-H 4 in PM group after receiving rabeprazole additionally as well as tmax of clopidogrel and MP-H 4 in all metablism subjects ，compared with clopidogrel alone（P＞0.05）. CONCLUSIONS ：Among CYP2C19 EM and IM subjects ，combined use of rabeprazole can significantly increase the exposure of clopidogrel and decrease the exposure of its active metabolite MP-H 4，but has no significant impact on clopidogrel and its active metabolite in CYP2C19 PM subjects.
ABSTRACT
Objective@#To evaluate the clinical effect of Jinghua Weikang capsule in treating peptic ulcer with intermingled heat and cold syndrome.@*Methods@#From January 2016 to December 2018, 90 patients of peptic ulcer with intermingled heat and cold syndrome in Changzhou Hospital of Traditional Chinese Medicine were divided into two groups by the random digital table method, with 45 cases in each group.The control group was treated with rabeprazole capsule, and the observation group were treated with rabeprazole capsule and Jinghua Weikang capsule.The gastroscopic performance, the main individual symptoms and TCM syndrome between the two groups were compared.@*Results@#The gastroscopic performance[42 cases(93.3%) were clinical cured, 1 case(2.2%) was significantly improved, 1 case(2.2%) was improved], TCM syndrome effect[38 cases(84.4%) were clinical cured, 4 cases(8.9%) were significantly improved, 2 cases(4.4%) were improved] in the observation group were significantly better than those in the control group[the gastroscopic performance: 35 cases(77.8%) were clinical cured, 5 cases(11.1%) were significantly improved, 3 cases(6.7%) were improved], TCM syndrome effect: 28 cases(62.2%) were clinical cured, 6 cases(13.3%) were significantly improved, 8 cases(17.8%) were improved](Z=-2.040, -2.463, all P<0.05). The improvement of TCM symptoms of epigastric pain which could be relieved by warmth and pressure, dry mouth with bitter taste, cool limbs were significantly better than those in the control group(χ2=6.154, 6.056, 7.174, all P<0.05).@*Conclusion@#Jinghua Weikang capsule can accelerate the repair of gastric mucous of patients with intermingled heat and cold syndrome, improve clinical syndrome, especially these symptoms: stomacha which can be relieved by warmth and pressure, dry mouth with bitter taste, cool limbs.
ABSTRACT
Objective To analyze the curative effect of teprenone capsule combined with quadruple therapy in the treatment of chronic atrophic gastritis.Methods From June 2013 to June 2017,one hundred and fifty patients with chronic atrophic gastritis admitted to the First Hospital of Ninghai County were retrospectively selected.According to different treatment schemes,they were divided into control group and observation group,with 75 patients in each group.The control group was treated with routine quadruple therapy, and the observation group was treated with teprenone capsule combined with quadruple therapy.The effective rate of the two groups was compared.Results The total effective rate of the observation group was 97.33% ,which was higher than 85.33% of the control group,the difference between the two groups was statistically significant(χ2 =3.197,P<0.05).After treatment,the levels of interleukin-8 and tumor necrosis factor - alpha in the observation group were ( 7.04 ± 1.03 ) ng/L, ( 41.02 ± 1.72)ng/L,respectively,which in the control group were (10.81 ± 1.63)ng/L,(57.35 ± 2.95) ng/L,respectively, the differences between the two groups were statistically significant (t=6.028,7.281,all P <0.05).The gastric mucosa score and the gastrin concentration in the observation group were (1.13 ± 0.32)points,(8.97 ± 2.33)pmol/L, respectively,which in the control group were ( 1. 82 ± 0. 61 ) points, ( 5. 36 ± 1. 52 ) pmol/L, respectively, the differences between the two groups were statistically significant ( t =5. 661, 6. 024, all P <0. 05 ). Conclusion Teprenone capsule combined with quadruple therapy can improve the clinical efficacy and reduce the degree of inflammation in patients with chronic atrophic gastritis,which is worthy of clinical application.
ABSTRACT
Objective To investigate the effect of low-dose aspirin combined with rabeprazole on the healing of peptic ulcer after hemostasis with aspirin-related peptic ulcer bleeding,and to explore the independent factors associated with ulcer healing failure.Methods A total of 138 patients with acute upper gastrointestinal hemorrhage in the Department of Gastroenterology of the Second Affiliated Hospital of Fujian Medical University from June 2016 to June 2018 were enrolled.The clinical data of 138 patients with upper gastrointestinal ulcer bleeding caused by aspirin were analyzed.The patients were randomly divided into two groups.Aspirin group (n =68) received aspirin 100 mg/d plus rabeprazole 80 mg/d,while the placebo group (n =70) received rabeprazole 80 mg/d plus placebo.The patients were treated for 8 weeks.Subjects with H.pylori infection were treated with standard quadruple therapy.Follow-up endoscopy was performed at the end of 8 weeks.The primary endpoint was the healing of peptic ulcers.Results The ulcer healing rate was 79.4％ (54/68) in the aspirin group and 84.3％ (59/70) in the placebo group.There was no statistically significant difference between the two groups (x2 =0.552,P ＞ 0.05).There were 5 cases of ulcer bleeding in aspirin group and placebo group.The rehaemorrhage rate was 7.4％ (5/68) and 7.1％ (5/70),respectively.There was no statistically significant difference between the two groups(x2 =0.002,P ＞ 0.05).Among the factors affecting the healing of aspirin-associated peptic ulcer,the healing rate was significantly associated with steroid use during treatment (x2 =6.135,P =0.041) and smoking status (x2 =5.616,P =0.018).Other factors,including age,hypertension,diabetes,alcohol history,history of previous ulcer bleeding,initial Helicobacter pylori status,and ulcer location did not affect ulcer healing.Conclusion After aspirin-associated peptic ulcer bleeding,continued low-dose aspirin plus rabeprazole did not affect the healing of peptic ulcers,and the use of steroids and smoking status are independent risk factors for ulcer healing.
ABSTRACT
Objective To explore the clinical effect of mosapride combined with rabeprazole in the treatment of elderly patients with reflux esophagitis .Methods Clinical data of 126 elderly patients with reflux esophagitis were retrospectively studied.64 cases in the study group were treated with mosapride combined with rabeprazole ,62 cases in the control group were treated with mosapride combined with omeprazole .The clinical effects between the two groups were compared.Results Before treatment,there were no statistically significant differences in the scores of pain of patients with heartburn,acid reflux and chest between the two groups (t =0.512,0.181,0.228,all P >0.05). After treatment,the symptom scores of the study group were significantly lower than those of the control group (t =3.689,4.892,5.571,all P <0.01).The clinical symptoms and esophageal mucosal total effective rate in the study group were significantly higher than those in the control group (96.88% vs.87.10%,93.75% vs.80.65%,χ2 =4.121,4.479,all P <0.05).The scores of quality of life scale of the study group were significantly higher than those of the control group in cognitive function ,mental function,physical function and social function (t =4.920,6.853, 4.153,6.163,all P <0.01).Conclusion Mosapride combined with rabeprazole in the treatment of elderly patients with reflux esophagitis can effectively relieve symptoms of heartburn ,acid reflux and chest pain,help patients with mucosa recovery as soon as possible ,improve the quality of life of patients,and it is worthy of clinical application .
ABSTRACT
Objective To investigate whether the effect of rabeprazole in treating gastroesophageal reflux disease is related to CYP2C19 gene polymorphisms.Methods 278 patients with gastroesophageal reflux disease confirmed by endoscopy and proton-pump inhibitor testing were enrolled in this study,including non erosive reflux disease (NERD) in 122 cases,the reflux esophagitis (RE) in 98 cases and Barrett esophagus in 58 cases.They were treated with rabeprazole for 8 weeks.GerdQ scores before and after the treatment were completed,endoscopy was performed again in patients with RE after treatment.The blood CYP2C19 genotyping was detected by matrix assisted laser desorption ionization time of flight mass spectrum(MALDI-TOF-MS).Results According to the genotype of CYP2C19,they were divided into extensive metabolizers,intermediate metabolizers and poor metabolizers,accounted for 39.57%,42.45% and 17.98%,respectively.There was no significant difference in GerdQ scores of three groups before treatment,and also had no significant difference after 8 weeks treatment,but in each subgroup GerdQ scores after treatment was decreased significantly than before treatment.The total effective rate of 98 patients with RE by endoscopy was 86.73%,but there was no significant difference in total effective rate of the three groups after treatment.Conclusion Rabeprazole is effective in the treatment of gastroesophageal reflux disease.Moreover,rabeprazole is less affected by CYP2C19 genotype and therefore its curative effect is more stable.
ABSTRACT
Objective To explore the clinical efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis.MethodsThe clinical data of 315 patients with reflux esophagitis from December 2015 to December 2016 in our hospital were retrospectively analyzed, were randomly divided into two groups according to the time of admission.The control group (157 cases)was treated with rabeprazole, the observation group (158 cases) given rabeprazole combined with mosapride treatment.The clinical symptom scores before and after treatment, the effective rate of treatment, the quality of life before and one month after treatment and three months after treatment of two groups were compared.ResultsAfter treatment,the symptoms scores of the two groups were significantly lower than those before treatment, but the the scores in the observation group were significantly lower than those in the control group (P<0.05);The total effective rate was 96.2% in the observation group, which was significantly higher than that in the control group (79.0%), the difference between the two groups was statistically significant (P<0.05);The quality of life scores of the two groups were significantly higher than that before treatment, but the scores of one months after treatment and three months after treatment in observation group were significantly higher than those in control group (P<0.05).ConclusionReflux esophagitis with rabeprazole combined with mosapride treatment is significant,can better improve the clinical symptoms of patients, improve the treatment efficiency, and improve the quality of life of patients.
ABSTRACT
Objective To evaluate clinical effect of rabeprazole combined with teprenone capsules in treatment of gastric ulcer by marking targeting biopsy and leptin.Methods A total of 118 patients with active gastric ulcer confirmed by endoscopy were randomly divided into two groups.Patients in the treatment group (n=60) were given rabeprazole 10 mg,bid,and teprenone capsules 50 mg,tid.Patients in the control group (n=58) were given rabeprazole 10 mg,bid.Both groups were treated continuously for 56 days.Before and after treatment,2 groups were labeled with biopsy,the clinical efficacy and the healing rate of two groups were recorded,the quality of healing and the expression of leptin were compared.The level of leptin was tested after treatment.Results After 10 days,the difference of clinical curative effect was not statistically significant (P>0.05).After 56 days,the difference of clinical curative effect was statistically significant (P<0.05);ulcer healing rate (93.33%)in treatment group was higher than that of control group (72.41%);ulcer healing quality (93.33%) in treatment group was higher than that of control group (58.62%);leptin level of treatment group was lower than that of the control group;gastric ulcer recurrence rate (3.8%) in treatment group was lower than that of the control group (24.0%) (all P<0.05).Conclusion Rabeprazole combined with teprenone in the treatment of gastric ulcer is better than rabeprazole.Marking targeting biopsy and leptin can be used to evaluate the healing quality of gastric ulcer more accurately,which can be an evaluation index of the quality of gastric ulcer healing and used as an indicator of the quality of gastric ulcer healing.
ABSTRACT
Objective To research the clinical efficacy of Sini decoction adjustment combined rabeprazole enteric capsules in treatment of gastroesophageal reflux cough and its effect on interleukin 8 (IL-8) and substance P (SP), the mast cell tryptase (MCT) levels.Methods 92 cases of gastroesophageal reflux cough were divided into control group and experimental group by drawing method , each had 46 cases.Control group were treated by rabeprazole enteric capsules, experimental group were treated with rabeprazole enteric capsules based on the control group.The curative effect, cough symptoms integral, IL-8, SP, MCT, gastric dynamic element (MOT) and the gastrin-releasing (GAS), pulmonary function and safety were compared between two groups.Results The total effective rate of experimental group(93.47%) was higher than the control group(76.08%), the difference was statistically significant (P<0.05).After treatment, the symptoms of experimental group(1.53 ±0.19) points was higher than the control groupthe difference was statistically significant(1.96 ±0.24)points,P<0.05.The IL-8, SP, MCT levels of experimental group were all lower than the control group ( P<0.05 ) .The MOT, GAS, and lung function of experimental group improved more significantly than the control group ( P <0.05 ) .The security between two groups has no significant difference .Conclusion The curative effect of Sini decoction adjustment combined Rabeprazole enteric capsules in treatment gastroesophageal reflux cough is obvious, can decrease IL-8, SP, MCT levels.
ABSTRACT
Objective To discuss the clinical application value of omeprazole and rabeprazole quadruple therapy on Helicobacter pylori associated peptic ulcer.Methods 360 patients with Helicobacter pylori associated peptic ulcer were selected.They were divided into two groups randomly.The rabeprazole group (180 cases) was treated with rabeprazole with quadruple therapy based,omeprazole group (180 cases) was treated with omeprazole quadruple therapy of short acting as the foundation,to observe and record the two groups of patients with clinical curative effect,the healing rate of ulcer,Helicobacter pylori eradication rate,histopathology and treatment of gastric mucosa during adverse reaction condition.Results The cure rate of rabeprazole group was significantly higher than that of omeprazole group (P ＜ 0.05).Compared the two groups before treatment,upper abdominal pain,abdominal discomfort,belching symptoms,no significant difference,the two groups after treatment in patients with upper abdominal pain,abdominal discomfort and belching percentage of patients decreased,and Rebela was the proportion of patients with lower group (P ＜ 0.05).After treatment,the rabeprazole group of ulcer healing rate 90.5％ (163/180),Helicobacter pylori eradication rate was 87.8％ (158/180),omeprazole group of ulcer healing rate was 70.5％ (127/180),Helicobacter pylori eradication rate was 72.2％ (130/180).The rabeprazole group of the healing rate of ulcer and Helicobacter pylori eradication rate were higher (P ＜ 0.05).Before treatment,there was no significant difference on gastric mucosal histopathological score between two groups.After treatment,two groups of gastric mucosa pathological score were decreased (P ＜ 0.05),no difference between the two groups.During the treatment,there was no significant difference on adverse reactions between two groups.Conclusion Rabeprazole with short acting quadruple therapy can significantly treat Helicobacter pylori causes,promote gastric mucosa repair,improve the clinical symptoms of peptic ulcer,the medication is safe,it is worthy of clinical use.
ABSTRACT
Objective To investigate the clinical effect of vitrectomy with single slice vitrectomy (PDR) and preoperative injection of monoclonal antibody (mAb) for treatment of proliferative diabetic retinopathy. Methods According to clinical treatment were randomly 64 cases of PDR patients in our hospital in February 2016-February 2017 were divided into observation group and control group, 32 cases (37 eyes) single vitreous body resection were included in the control group, the remaining 32 cases (41 eyes) from preoperative intravitreal injection 0.5mg Lei Zhu monoclonal antibody drug treatment after resection of vitreous body were included in the observation group. The operation time, the best corrected visual acuity before and after the operation were recorded and compared between the two groups. The incidence of iatrogenic hiatus, frequency use, vitreous volume and hyphema were recorded in the two groups. Results The operation time of the observation group was (96.47±12.67) min, which was significantly shorter than that of the control group (128.56±13.78) min (P<0.05). The best corrected visual acuity of the two groups was basically at the same baseline level, and the corrected visual acuity of the 30d observation group was obviously improved and better than that of the control group (P<0.05). Compared with the control group, the incidence of iatrogenic hiatus, electrocoagulation, vitreous volume and hyphema was lower in the observation group (P<0.05). Conclusion Intravitreal injection of ranibizumab therapy after resection of vitreous body regimen in the treatment of PDR is safe and effective, not only helps to shorten the operation time, and lower incidence of postoperative complications, postoperative recovery of visual acuity is good, it is worthy of clinical popularization and wide application of bed.
ABSTRACT
OBJECTIVE:To investigate the effectiveness and safety of 2 kinds of proton pump inhibitors in the treatment of coronary heart disease (CHD).METHODS:In retrospective study,a total of 92 patients with CHD were selected from our hospital during Jun.2015-May 2016,and then divided into rabeprazole group (30 cases),esomeprazole group (32 cases) and control group (30 cases) according to therapy plan.Control group received basic therapy plan.Rabeprazole group and esomeprazole group were additionally given sodium rabeprazole enteric-coated tablets and Esomeprazole magnesium enteric-coated tablets 20 mg,po,bid,on the basis of control group.A treatment course lasted for 30 d,and both medication groups received 2 courses of treatment.Blood uric acid levels,urine pH values,blood ion levels (Na+,K+,Ca2+,Cl-) were detected before and after treatment.The occurrence of cardiovascular adverse events,coronary adverse events and other adverse events were observed in 2 groups during treatment.RESULTS:Before treatment,there was no statistical significance in above indexes among 3 groups (P＞0.05).After treatment,the levels of blood uric acid,K+ (except for control group),Ca2+ and Cl-were decreased significantly,while urine pH values and blood Na+ levels were increased significantly;the levels of blood uric acid and Ca2+ in rabeprazole group and esomeprazole group were significantly lower than control group,while urine pH value and blood Na+ level were significantly higher than control group,with statistical significance (P＜0.05).After treatment,the level of blood uric acid in rabeprazole group was significantly lower than esomeprazole group,with statistical significance (P＜0.05).But there was no statistical significance in urine pH values or ion levels between 2 groups (P＞0.05).Compared with control group,the incidence of acute thrombosis in rabeprazole group and esomeprazole group were decreased significantly,and the incidence of joint swelling and pain were increased significantly,with statistical significance (P＜0.05).There was no statistical significance in the incidence of coronary adverse events among 3 groups (P＞0.05).CONCLUSIONS:Rabeprazole and esomeprazole can significantly reduce the level of blood uric acid and the incidence of acute thrombosis,increase urine pH value and blood Na+ levels,decrease blood Ca2+ level and increase the risk of fracture or hypocalcemia in patients with CHD.Therefore,the dosage regimen should be adjusted according to the specific situation of patients in clinical practice
ABSTRACT
Objective To observe the clinical effect of Shumu-Yuntu-Zhike decoction with conventional treatment for the Gastroesophageal Reflux Cough (GERC).Methods A total of 64 patients with GERC were randomly divided into the conventional treatment group and the combined treatment group, 32 in each. The conventional treatment group took the Rabeprazole capsule and Mosapride Citrate Tablets, and the combined treatment group received the traditional prescription of Shumu-Yuntu-Zhike decoction on the basis of the conventional therapy. Two groups were treated for 8 weeks and evaluated the effect with the Visual analogue scale (VAS), Reflux diagnostic questionnaire (RDQ) and Chronic cough impact questionnaire (CCIQ) before and after 4 and 8 weeks' treatment.Results After 4 week treatment, the VAS (4.47 ± 1.32vs. 6.22 ± 1.34;t=-5.859,P<0.01), CCIQ (32.60 ± 5.83vs. 47.32 ± 5.56,t=-11.548,P<0.01) in the combined treatment group decreased significantly than the conventional group, but the RDQ (13.62 ± 2.89vs. 13.67 ± 2.77;t=-0.079, P=0.937) showed no significant difference between the two groups. After 8 weeks' treatment. After 8 week treatment, the VAS (2.57 ± 1.69vs. 4.55 ± 2.06;t=-4.676,P<0.01), CCIQ (12.47 ± 3.41vs. 23.47 ± 3.55;t=-14.126,P<0.01) in the combined treatment group decreased significantly, but the RDQ (9.18 ± 2.77vs. 9.3 ± 2.43,t=-0.202,P=0.841) showed no significant difference between the two groups. After the treatment, the total effective rate of combined treatment group was 90.6% (29/32), while the control group was 68.7% (22/32). There was significant difference between the two groups (χ2=4.730,P=0.030).Conclusions The therapy of Shumu-Yuntu-Zhike decoction combined with conventional therapy can relieve the symptom of gastroesophageal reflux cough.
ABSTRACT
Objective To investigate the clinical effect of Bella in the treatment of gastric ulcer. Methods According to the different treatment methods will be January 2015-2017 year in March in our hospital 120 cases of patients with gastric ulcer group: control group was treated with amoxicillin + clarithromycin + omeprazole treatment, the observation group used amoxicillin + clarithromycin + ray Bela with before and after treatment; the two groups were observed for clinical symptom score changes, the level of IL-2/IL-6/CRP the incidence of adverse reactions, and the relevant data for comparative analysis. Results Amoxicillin + clarithromycin + ray was Bella (observation group) in the treatment of gastric ulcer is better than omeprazole + amoxicillin + clarithromycin (control group) treatment, clinical symptoms score changes better than the control group, IL-2/IL-6/CRP levels than the control group, the difference was statistically significant (P<0.05); two groups of patients the adverse reaction rate comparison, the difference was not statistically significant. Conclusion The gastric ulcer patients choose amoxicillin + clarithromycin + ray Bella with significant curative effect, can improve the clinical symptoms and IL-2/IL-6/CRP level of patients, and will not increase the incidence of adverse reactions, it is worthy of widely used in the treatment of patients with gastric ulcer.
ABSTRACT
Objective To investigate the efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis. Methods A total of 92 patients with reflux esophagitis admitted from April 2016 to April 2017 in our hospital were divided into study group and routine group (n = 46). The routine group was treated with omeprazole and Mosapride,the study group was treated with rabeprazole and mosapride. The clinical efficacy and adverse reactions in the two groups were observed and compared. Results The total effective rate was 91.30％ in the study group and 76.09％ in the conventional group, the difference was statistically significant (P<0.05). The total effective rate of reflux symptoms, esophageal irritation and esophageal irritation was significantly higher in the study group than in the conventional group (P<0.05)The adverse reaction rate was 4.35％ in the study group and 6.52％ in the conventional group, the difference was not statistically significant (P<0.05). Conclusion In the course of clinical treatment of reflux esophagitis, attention should be paid to the two aspects of acid suppression and gastric motility. In the inhibition of acid, the effect of Bella is obviously higher than that of omeprazole. In gastric motility, mosapride in clinical effect is better. Reflux esophagitis by rabeprazole combined with mosapride treatment, clinical efficacy is significant, and adverse reaction rate is low, safe and reliable, worthy of clinical application.
ABSTRACT
Objective To investigate the clinical effect of regulating Spleen Yangwei Decoction combined with rabeprazole in the treatment of rheumatoid gastritis with hot and humid obstruction.MethodsFrom April 2013 to February 2015, 88 patients with reflux gastritis caused by cholecystectomy in our hospital were selected as the subjects.TCM syndrome differentiation was hot and humid type, and random number table was divided into observation Group and control group of 44 cases, the control group given rabeprazole, citrate xylapril tablets and other Western medicine treatment, observation group on the basis of this plus self-adjusting spleen and stomach soup, are treated for 3 months, (TNF-α) and interleukin-8 (IL-8) levels were measured by enzyme-linked immunosorbent assay (ELISA) in the two groups before and after treatment, and the quality of life scale was used to evaluate the levels of tumor necrosis factor-α (TNF-α) (QOL) and digital pain score (NRS) were compared between the two groups to improve the quality of life and pain, and to observe the recurrence of bile reflux and adverse reactions.ResultsThe effective rate was 93.18% in the observation group and 77.27% higher than that in the control group (P<0.05).The QOL score (121.29±1.88) in the observation group was higher than that in the control group(P<0.05).The results of bile test showed that the levels of pg/mL, IL-8 (8.58±1.64) pg/mL and NRS (2.10±0.71) were lower than those in the control group (P<0.05).There was no significant difference between the observation group (11.36%) and the control group (4.54%).The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P< 0.05).ConclusionModified Spleen Yangwei Decoction combined with rabeprazole can effectively treat rheumatoid reflux gastritis, reduce bile reflux, improve the level of inflammatory factors, quality of life and pain, and mild adverse reactions, it is worth in the clinical promotion application.
ABSTRACT
Objective To explore the clinical efficacy of different course of colloidal bismuth pectin quadruple therapy for Helicobacter pylori (Hp) eradication in patients with peptic ulcer (PU) and the condition of digestive tract symptom improvement by a single-center,prospective,random-control study,and to provide theoretic evidence for clinicians on the selection of the schedule upon unti-PU Hp infection.Methods 90 active stage PU initial treated patients with Hp infection diagnosed by gastroscope were enrolled randomly.The patients were given oral unti-Hp treatment including rabeprazole sodium (20mg,2/day),clarithromycin (0.5 g,2/day),amoxicillin (1 g,2/day) and colloidal bismuth subcitrate (0.6g,2/day),and were divided into three groups with different course of treatment randomly acconding to the digital table:A group (7 days),B group (10 days) and C group (14 days),each group including 30 cases.The condition of digestive symptom improvement and adverse effect were recorded during treatment.After the quadruple therapy,and at least 4 weeks without using proton pump inhibitor (PPI) and antibiotics,the outcome of Hp eradication was evaluated by 14C carbamide breath test (14C-UBT).The difference of Hp eradication among the three groups was analyzed.The clinical efficacy of different course was evaluated and the cost/effect was calculated.Results The Hp eradication rates of the A group,B group and C group were 46.67％,73.33 ％ and 76.67％,respectively,the differences was statistically significant (x2 =7.184,P =0.028).After treatment,the scores of the digestive symptom of the three groups were lower than before treatment (A group:t =3.272,P =0.038;B group:t =6.424,P ＜ 0.001;C group:t =8.086,P ＜ 0.001),and the scores of the B group and C group were lower than A group (F =3.110,P =0.028),while the three groups showed no obvious difference in the incidence of adverse effects(x2 =0.274,P =0.872).The C/E of the A group,B group and C group were 4.7,4.3 and 5.7,respectively.Conclusion The 10-day and 14-day course of colloidal bismuth pectin quadruple therapy including rabeprazole sodium,clarithromycin,amoxicillin and colloidal bismuth subcitrate demonstrated better clinical efficacy of unti-PU Hp infection than the 7-day treatment,with obvious improvement of digestive symptom,and the 10-day quadruple therapy has the best economical advantage.
ABSTRACT
A highly sensitive ultra-fast LC-MS/MS based bioanalytical method for the measurement of Rabeprazole in human plasma was developed and validated using 13C-D3-Rabeprazole as internal standard. Rabeprazole is a sulfabenzimidazole class of compounds, setting chromatography for these classes of compounds is always a challenge. Rabeprazole was extracted from human plasma samples by liquid-liquid extraction (LLE) and separated on a short reverse phase Ascentis® Express C18, 50 mm × 4.6 mm, 2.7 μm column by isocratic elution with 40% 10 mM ammonium acetate solution and 60% acetonitrile at a flow rate of 0.700 mL/min. Rabeprazole and its labeled internal standard were detected by multiple reaction monitoring (MRM) mode using electro spray ionization (ESI). All the validation parameters as per current guidelines like specificity, selectivity, accuracy, precision, recovery, matrix factor, haemolysis effect and stability are assessed in human plasma. Rabeprazole was found to be linear over a range of 0.1 ng/mL to 150 ng/mL in human plasma. LLOQ of0.1 ng/mL is sensitive enough for application to different clinical studies. The intra- and inter-day precision was less than 10% and accuracy was within -3.33 to 10.00%. Recovery (70%) was consistent across the linear dynamic range of the method. The validated method is a simple, accurate, precise and robust to measure Rabeprazole in human plasma and could be used for application to any format of clinical studies.
ABSTRACT
OBJECTIVE:To observe the efficacy and safety of weifuchun tablet combined with rabeprazole enteric-coated tablet in the treatment of chronic gastritis with reflux esophagitis. METHODS:894 gastritis patients with reflux esophagitis were random-ly divided into control group (407 cases) and observation group (487 cases). Control group was given 10 mg Rabeprazole enter-ic-coated tablet,once a day;observation group was additionally given 1 440 mg Weifuchun tablet,orally,3 times a day. The treat-ment course for both groups was 4-8 weeks. Clinical efficacy,microscopic examination grading,total symptom scores,self-rating anxiety scores(SAS),self-rating depression scores(SDS),quality of life scale score(QOLS),Memorial University of Newfound-land Scale of Happiness score(MUNSH) of reflux esophagitis before and after treatment,and incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the dif-ference was statistically significant(P0.05);after treatment,the micro-scopic examination grading cases in 2 groups were significantly superior to before,observation group was superior to control group,total symptom scores,SAS and SDS scores were significantly lower than before,observation group was lower than control group,QOLS and MUNSH scores were significantly higher than before,observation group was higher than control group,the dif-ferences were statistically significant(P0.05). CONCLUSIONS:Weifuchun tablet combined with rabeprazole enteric-coated tablet has better efficacy than only rabeprazole in the treatment of chronic gastritis with reflux esophagitis,it can relieve clinical symptoms of pa-tients,with better safety.
ABSTRACT
Objective To evaluate the efficacy and safety of rabeprazole sodium injection in the treatment of non-esophageal variceal upper gastrointestinal bleeding in comparison with the positive control,omeprazole.Methods From January 2010 to January 2011,231 patients with non-esophageal variceal upper gastrointestinal bleeding from 20 hospitals were divided into rabeprazole group and omeprazole group in this multicenter,randomized,blind,parallel-group,positive drug controlled clinical trial.Hemostasis rate in 72 hours was the primary endpoint.Hemostasis rate in 120 hours,time to hemostasis,blood transfusion volume and the rate of switching treatments were the secondary endpoint.And safety was also analyzed.Chi square test and Wilcoxon rank sum test were performed for statistical analysis.Results At 72 hours after treatment,the hemostasis rates of rabeprazole group and omeprazole group were 98.20％(109/111)and 98.25％(112/114), respectively, and the difference was not statistically significant (P＞0.05).The 95％ confidence interval (CI) of the rate difference between the two group was-3.50 ％ to 3.40 ％.The result of non-inferiority test indicated that the lower limit of the 95％CI of the rate difference between the two groups was-2.95％ (U=5.652,P＜0.01),and rabeprazole group was not inferior to omeprazole group.At 12 hours after treatment,the hemostatic rates of rabeprazole group and omeprazole group were 63.06％(70/111) and 53.51％(61/114),respectively,and there was no statistically significant difference (P＞0.05).At 120 hours after treatment,the hemostasis rates of rabeprazole group and omeprazole group were 99.10 ％ (110/111) and 98.25 ％ (112 /114),and there was no statistically significant difference (P＞0.05).The median time of hemostasis of two groups was 24 hours.During the treatment,there were two cases and seven cases of rabeprazole group and omeprazole group received blood transfusions,respectively;there were 0.90％ (1/111) and 2.63 ％ (3/114) patients switched to other treatment,and no statistically significant difference was found (P＞0.05).The rates of adverse event of rabeprazole group and omeprazole group were 11.61％ (13/112) and 5.26％ (6/114),respectively.The rates of adverse reaction were 6.25％ (7/112) and 4.39％ (5/114),respectively.The differences in the rates of adverse event and adverse reaction between two groups were not statistically significant(both P＞0.05).Conclusion Rabeprazole sodium injection is an effective and safe drug in the treatment of non-esophageal variceal upper gastrointestinal bleeding.